Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of sac-TMT (MK-2870) plus pembrolizumab followed by carboplatin/paclitaxel plus pembrolizumab versus chemotherapy plus pembrolizumab as neoadjuvant treatment for high-risk early triple-negative or HR-low/HER2-negative breast cancer
CTR20253282Phase 3Active
- Sponsor
- MSD
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in breast cancer, triple-negative breast cancer (TNBC), sponsored by MSD. Started Aug 2025; status: active.
02
Drugs
sacituzumab tirumotecan
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20253282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253282.